CD8A and neoplasm: A notable study demonstrated that a personalized mRNA neoantigen vaccine (autogene cevumeran) could induce a substantial population of durable, polyfunctional CD8+ T cells targeting tumor-specific neoantigens in PDAC patients (98, 99).